Skip to main content

ADVERTISEMENT

ibrutinib

Conference Coverage
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
12/09/2020
Journal of Clinical Pathways
Research in Review
02/27/2017
JCP Editors
Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...
Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...
...
02/27/2017
Journal of Clinical Pathways